AAAAI: Skin Lipid Biomarkers May Predict Atopic Dermatitis and Food Allergy Risk

In an interview with Pharmacy Times, Jessica Hui-Beckman, MD, allergist and immunologist at National Jewish Health in Denver, Colorado, discussed the findings presented in her session, “Skin Lipid Biomarkers that Characterize Atopic Dermatitis and Food Allergic Patients,” at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting in Philadelphia, Pennsylvania.

Hui-Beckman highlighted emerging evidence that abnormalities in the skin barrier can be detected before the clinical onset of atopic dermatitis (AD), underscoring the importance of early identification and intervention.

She explained that multiple birth cohort studies have demonstrated decreased protein-bound ceramides in infants with otherwise normal-appearing skin who later develop AD. These ceramides are essential structural components of the outermost skin barrier. Additionally, affected infants exhibit increased immature lipid species, suggesting impaired lipid differentiation. In patients with established AD, Staphylococcus aureus colonization further disrupts the barrier by inhibiting fatty acid elongation, shortening key lipid chains necessary for structural integrity.

Distinct lipid alterations are also observed in food allergy. Although immature lipid species are decreased, protein-bound ceramides may be increased, potentially representing a compensatory response. Overall, disruptions in lipid composition weaken the skin barrier, allowing allergens, microbes, and irritants to penetrate more easily and trigger pro-inflammatory cytokines such as TSLP and IL-33, promoting type 2 immune skewing.

“The big key is protecting the skin barrier and treating the skin barrier.” — Jessica Hui-Beckman, MD

Hui-Beckman noted that while data linking lipid biomarkers to disease severity remain limited, emerging cytokine research may offer future insights into progression. She emphasized that barrier restoration is central to both management and potential prevention strategies, though prevention data remain mixed and may depend on the type of emollient used.

For pharmacists, these findings reinforce the importance of counseling on adherence to prescribed topicals, understanding newer barrier-restoring therapies, and recognizing the broader systemic implications of AD, including its association with food allergy.